Shares of Durata Therapeutics (NASDAQ:DRTX) , a prior to Friday clinical-stage biopharmaceutical company developing unique therapies to treat infectious diseases and acute illnesses, fell as much as 15% after the Food and Drug Administration approved Dalvance (previously dalbavancin) for the treatment of acute bacterial skin and skin structure infections, or ABSSSI. Durata Therapeutics Inc. (NASDAQ:DRTX) weekly performance is -8.12%. On last trading day company shares ended up $15.05. Analysts mean target price for the company is $19.72. Durata Therapeutics Inc. (NASDAQ:DRTX) distance from 50-day simple moving average (SMA50) is 6.13%.
Biodel Inc. (NASDAQ:BIOD) chief financial officer will be resigning effective May 30, the company disclosed Friday in a U.S. Securities and Exchange Commission filing. Biodel Inc. (NASDAQ:BIOD) shares fell -0.50% in last trading session and ended the day on $2.01. BIOD gross Margin is – and its return on assets is -49.70%.Biodel Inc. (NASDAQ:BIOD) quarterly performance is -37.77%.
CEL-SCI Corporation (NYSEMKT:CVM) announced that the University of Cincinnati Cancer Institute is the latest medical center in the U.S. to join its Phase III head and neck cancer clinical trial of its investigational cancer immunotherapy treatment Multikine* (Leukocyte Interleukin, Injection). CEL-SCI’s study is already active in dozens of clinical centers in 12 countries and is expected to expand to a total of 20 countries with an estimated 880 patients to be enrolled by the end of 2015. According to the American Society of Clinical Oncology, head and neck cancers account for about 3% to 5% of all cancers in the United States. CEL-SCI Corporation (NYSEMKT:CVM) shares moved down -2.88% in last trading session and was closed at $1.01, while trading in range of $0.98 – $1.04. CEL-SCI Corporation (NYSEMKT:CVM) year to date (YTD) performance is 71.19%.
YY Inc. (ADR) (NASDAQ::YY) recently launched its educational platform (100.com) and has received positive feedback from both students and teachers. YY Inc. (ADR) (NASDAQ:YY) ended the last trading day at $61.62. Company weekly volatility is calculated as 6.69% and price to cash ratio as 4.52.YY Inc. (ADR) (NASDAQ:YY) showed a positive weekly performance of 9.18%.
Pfizer Inc. (NYSE: PFE) has abandoned any effort to purchase AstraZeneca Plc (NYSE: AZN) for $117 billion. The US drug maker issued a statement saying that the bid of $117 billion rejected by its British competitor was of “full value.” In turn, AstraZeneca informed the public as well as Pfizer that it welcomed the chance to continue the building of momentum that the two companies have already shown. Pfizer Inc. (NYSE:PFE) net profit margin is 81.20% and weekly performance is 1.13%. On last trading day company shares ended up $29.61. Analysts mean target price for the company is $33.97. Pfizer Inc. (NYSE:PFE) distance from 50-day simple moving average (SMA50) is -2.93%.